Literature DB >> 16234240

Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes.

Anneliese D Recklies1, Hua Ling, Chantal White, Suzanne M Bernier.   

Abstract

Elevated levels of CHI3L1 (chitinase-3-like protein 1) are associated with disorders exhibiting increased connective tissue turnover, such as rheumatoid arthritis, osteoarthritis, scleroderma, and cirrhosis of the liver. This secreted protein is not synthesized in young healthy cartilage, but is produced in cartilage from old donors or patients with osteoarthritis. The molecular processes governing the induction of CHI3L1 are currently unknown. To elucidate the molecular events involved in CHI3L1 synthesis, we investigated two models of articular chondrocytes: neonatal rat chondrocytes, which do not express CHI3L1, and human chondrocytes, which express CHI3L1 constitutively. In neonatal rat chondrocytes, the inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 potently induced steady-state levels of CHI3L1 mRNA and protein secretion. Treatment of chondrocytes with TNF-alpha for as little as 1 h was sufficient for sustained induction up to 72 h afterward. Using inhibitors selective for the major signaling pathways implicated in mediating the effects of TNF-alpha and interleukin-1, only inhibition of NF-kappaB activation was effective in curtailing cytokine-induced expression, including after removal of the cytokine, indicating that induction and continued production of CHI3L1 are controlled mainly by this transcription factor. Inhibition of NF-kappaB signaling also abolished constitutive expression by human chondrocytes. Thus, induction and continued secretion of CHI3L1 in chondrocytes require sustained activation of NF-kappaB. Selective induction of CHI3L1 by cytokines acting through NF-kappaB coupled with the known restriction of the catabolic responses by CHI3L1 in response to these inflammatory cytokines represents a key regulatory feedback process in controlling connective tissue turnover.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234240     DOI: 10.1074/jbc.M510146200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation.

Authors:  Dafna Bonneh-Barkay; Stephanie J Bissel; Julia Kofler; Adam Starkey; Guoji Wang; Clayton A Wiley
Journal:  Brain Pathol       Date:  2011-12-22       Impact factor: 6.508

2.  YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers.

Authors:  Christian B Brøchner; Julia S Johansen; Lars A Larsen; Mads Bak; Hanne B Mikkelsen; Anne Grete Byskov; Claus Yding Andersen; Kjeld Møllgård
Journal:  J Histochem Cytochem       Date:  2011-12-01       Impact factor: 2.479

3.  A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40.

Authors:  Sandeep K Singh; Reetika Bhardwaj; Katarzyna M Wilczynska; Catherine I Dumur; Tomasz Kordula
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

4.  YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Richard J Perrin; Catherine M Roe; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Mark A Mintun; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Gina D'Angelo; James P Malone; R Reid Townsend; John C Morris; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2010-11-15       Impact factor: 13.382

5.  Chitinase-like proteins in lung injury, repair, and metastasis.

Authors:  Chun Geun Lee; Charles S Dela Cruz; Bing Ma; Farida Ahangari; Yang Zhou; Ruth Halaban; Mario Sznol; Jack A Elias
Journal:  Proc Am Thorac Soc       Date:  2012-05

6.  Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation.

Authors:  Kristoffer Mads Henningsen; Brian Nilsson; Julia S Johansen; Xu Chen; Steen Pehrson; Jesper Hastrup Svendsen
Journal:  Inflamm Res       Date:  2009-12-10       Impact factor: 4.575

Review 7.  Circulating tumor cell interactions with macrophages: implications for biology and treatment.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Transl Lung Cancer Res       Date:  2017-08

8.  Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy.

Authors:  Lene Surland Knudsen; Merete Lund Hetland; Julia Sidenius Johansen; Henrik Skjødt; Niels Daugaard Peters; Ada Colic; Karin Grau; Hans Jørgen Nielsen; Mikkel Ostergaard
Journal:  Biomark Insights       Date:  2009-09-23

9.  Gene expression profiling in the lung tissue of cynomolgus monkeys in response to repeated exposure to welding fumes.

Authors:  Jeong-Doo Heo; Jung-Hwa Oh; Kyuhong Lee; Choong Yong Kim; Chang-Woo Song; Seokjoo Yoon; Jin Soo Han; Il Je Yu
Journal:  Arch Toxicol       Date:  2010-03       Impact factor: 5.153

Review 10.  YKL-40--an emerging biomarker in cardiovascular disease and diabetes.

Authors:  Camilla N Rathcke; Henrik Vestergaard
Journal:  Cardiovasc Diabetol       Date:  2009-11-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.